MASCT is under clinical development by HRYZ (ShenZhen) Biotech and currently in Phase I for Osteosarcoma. According to GlobalData, Phase I drugs for Osteosarcoma have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MASCT’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MASCT overview

Cellular immunotherapy is under development for the treatment of soft tissue sarcoma, bladder cancer, osteosarcoma, pancreatic cancer, nasopharyngeal cancer, urothelial cell carcinoma, bile duct cancer (cholangiocarcinoma) and urethral cancer. It is administered as intravenous drip. The therapeutic candidate constitutes autologous dendritic cells loaded with antigens called as multiple antigens specific cellular therapy (MASCT). It was also under development for hepatocellular carcinoma, gastric cancer, gastroesophageal adenocarcinoma, triple-negative breast cancer, ovarian cancer, adenocarcinoma of the gastroesophageal junction, advanced solid tumors including lung cancer, colon cancer, prostate cancer,

For a complete picture of MASCT’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.